The trademark application RHEUMIN8 was filed by AbbVie Biotechnology Ltd, a corporation established under the laws of "BM" (the "Applicant"). The application was published for oppositions on February 28, 2022, and it was registered by office on June 7, 2022 without any oppositions.
The application was filed in English (French was selected as the second language).